Bayer receives first approval for Lynkuet in UK as treatment for vasomotor symptoms associated with menopause
The UK authorization is based on positive results from the Phase III OASIS-1, -2, and -3 trials
The UK authorization is based on positive results from the Phase III OASIS-1, -2, and -3 trials
Vevzuo is authorized for the prevention of skeletal related events in adults with advanced malignancies involving bone
Aumolertinib can be used in patients who have tested positive for a mutation in a gene called epidermal growth factor receptor
YESINTEK is indicated for the treatment of adults and children from the age of 6 years and olde
CuraTeQ Biologics receives approval for biosimilar Zefylti from UK’s MHRA
Blenrep combinations could redefine treatment as early as first relapse where more effective options are needed
PCC has secured the commercialization rights for the EU, UK, and Norway and will be responsible for distributing Neoatricon in these regions
Talicia is also approved and launched in the UAE and additional countries may accept UK MHRA approvals as a reference for their own marketing approval processes
The launch follows the approval from the Medicines and Healthcare Products Regulatory Agency (MHRA), U.K.
Subscribe To Our Newsletter & Stay Updated